Glibenclamide but not other sulphonylureas stimulates release of neuropeptide Y from perifused rat islets and hamster insulinoma cells

in Journal of Endocrinology
Authors:
RN Kulkarni
Search for other papers by RN Kulkarni in
Current site
Google Scholar
PubMed Close
,
ZL Wang
Search for other papers by ZL Wang in
Current site
Google Scholar
PubMed Close
,
RM Wang
Search for other papers by RM Wang in
Current site
Google Scholar
PubMed Close
,
DM Smith
Search for other papers by DM Smith in
Current site
Google Scholar
PubMed Close
,
MA Ghatei
Search for other papers by MA Ghatei in
Current site
Google Scholar
PubMed Close
, and
SR Bloom
Search for other papers by SR Bloom in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.1677/joe.0.1650509
Volume/Issue:
Volume 165: Issue 2
Article Type:
Other
Page Range:
509–518
Online Publication Date:
01 May 2000
Free access

Sign up for journal news

We have studied the effects of first and second generation sulphonylureas on the release of insulin and neuropeptide tyrosine (NPY) from hamster insulinoma tumour (HIT T15) cells and isolated rat islets. In the presence of 5.5 mmol/l glucose all sulphonylureas stimulated insulin release from the HIT cells (P<0.01 ANOVA, n> or =4) but only glibenclamide (GLIB, 10 micromol/l) stimulated the release of NPY (mean+/-s.e.m. control 11.1+/-1.3 vs GLIB 28.4+/-4.1 fmol/h per 10(6) cells, P<0001, n=16). In isolated perifused rat islets both glibenclamide (10 micromol/l) (control 3.5+/-0.3 vs GLIB 6. 3+/-0.2 fmol/min per islet, P<0.01, n=6) and tolbutamide (50 micromol/l) (control 4.7+/-0.1 vs TOLB 6.7+/-0.3 fmol/min per islet, P<0.01, n=6) enhanced glucose (8 mmol/l)-stimulated insulin release. However, only glibenclamide stimulated the release of NPY from the islets (control 3.4+/-0.8 vs GLIB 24.5+/-5 attomol/min per islet, P<0.01, n=6). Similar results were obtained in islets isolated from dexamethasonetreated rats. Glibenclamide treatment of HIT cells showed a prompt insulin release (10 min) while NPY secretion was slower (60 min), suggesting that internalization of the sulphonylurea is required to stimulate NPY release. Glibenclamide, the most common oral therapeutic agent in type 2 diabetes mellitus, is associated with release of the autocrine insulin secretion inhibitor, NPY.

Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 567 446 106
PDF Downloads 198 64 10

 

  • Collapse
  • Expand
Print ISSN:
0022-0795
Online ISSN:
1479-6805
Page(s):
10
Article Type:
Other
Print Publication Date:
01 May 2000
Online Publication Date:
01 May 2000